Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr-Jun;29(2):208-13.
doi: 10.20524/aog.2016.0014.

Nucleos(t)ide analogues for the prevention of hepatitis B recurrence after liver transplantation do not affect serum phosphorus levels

Emmanouil Sinakos  1 , Nikolaos Antoniadis  2 , Ioannis Goulis  1 , Evangelos Cholongitas  1 , Stefania Kiapidou  1 , Ekaterini Tsakni  2 , Themistoklis Vasiliadis  3 , Vassilios Papanikolaou  2 , Evangelos Akriviadis  1
Affiliations

Nucleos(t)ide analogues for the prevention of hepatitis B recurrence after liver transplantation do not affect serum phosphorus levels

Emmanouil Sinakos et al. Ann Gastroenterol. 2016 Apr-Jun.

Abstract

Background: Nucleos(t)ide analogues (NAs) constitute the backbone of treatment for the prevention of hepatitis B virus recurrence after liver transplantation (LT). Decline in serum phosphorus levels is a common side effect of nucleotide therapy. Our aim was to assess the impact of nucleotide treatment on the occurrence of hypophosphatemia after LT and determine possible predictors.

Methods: We retrospectively analyzed data from liver transplant recipients who had been transplanted for various indications. All patients were evaluated every 3 months. Each patient was considered to be having hypophosphatemia when at least one value of serum phosphorus ≤2.5 mg/dL was detected.

Results: In total, 109 patients [83 males (76%)] with a mean age of 55±10 years were included. 46/67 (67%) patients with hepatitis B received a nucleotide. The rate of hypophosphatemia (55%) was not different between patients with hepatitis B and those transplanted for other indications (62%). Patients receiving a nucleotide did not run a greater risk of hypophosphatemia than patients receiving only nucleosides (59% vs. 48%, P=0.39). Male gender and everolimus use were associated with the occurrence of hypophosphatemia in patients with hepatitis B. In multivariate analysis only gender was associated with hypophosphatemia (odds ratio 11.43, 95%CI -2.11 to -0.49; P=0.0025).

Conclusions: Hypophosphatemia occurs in more than half of liver transplant recipients regardless of the indication for LT. Male gender and everolimus use seem to predispose to hypophosphatemia, whereas the type of antiviral agent does not.

Keywords: Hepatitis B; hypophosphatemia; nucleos(t)ide; prophylaxis; transplantation.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None

Figures

Figure 1
Figure 1
Distribution of nucleos(t)ide analogues that were used in patients transplanted for advanced liver disease due to chronic hepatitis B
Figure 2
Figure 2
Occurrence of hypophosphatemia according to nucleos(t)ide analogue regimen
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation:a systematic review. Am J Transplant. 2013;13:353–362. - PubMed
    1. Kamar N, Huart A, Tack I, Alric L, Izopet J, Rostaing L. Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients. Clin Nephrol. 2009;71:36–42. - PubMed
    1. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B:final long-term results. Liver Transpl. 2007;13:349–360. - PubMed
    1. Heathcote EJ, Marcellin P, Buti G, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140:132–143. - PubMed
    1. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455. - PubMed

LinkOut - more resources